SUBSCRIBE
SUBSCRIBE
News   Policy

AstraZeneca PLC Responds to U.S. Regulator Decision on Blood-Thinner Brilinta

January 21, 2011 | 
1 min read
Bloomberg -- AstraZeneca Plc told the U.S. Food and Drug Administration that high-dose aspirin most likely caused different results in a test of the Brilinta blood thinner, citing an analysis requested by the regulator.
Regulatory
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Regulatory
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
February 25, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
February 25, 2026
 · 
2 min read
 · 
Heather McKenzie
Capitol Hill COVID-19 blood testing, abstract virus testing during pandemic concept, State Building Washington DC, USA, 3d illustration
FDA
Opinion: Balancing Safety Access in Rare Disease—Lessons From Sarepta
February 25, 2026
 · 
6 min read
 · 
Joshua R. Mansbach
screenshot of Marty Makary speaking on the Megyn Kelly Show
Vaccines
FDA’s Makary Backs mRNA Vaccines but Says Companies ‘Can Fund Their Own Research’
February 24, 2026
 · 
2 min read
 · 
Tristan Manalac